CPhI Online

Univercells launches new cell and gene focused CDMO Exothera

19 Mar 2020

Exothera's Jumet site

A new contract development and manufacturing organisation to support cell and gene developers with process development and production of viral vectors has been launched by bioprocessing provider Univercells.

In a statement, Univercells said the company, Exothera, has been created to help alleviate a current lack of capacity and scarcity of bioprocessing expertise in the cell and gene manufacturing sector.

“This new focus will enable our team to leverage expertise with innovation to overcome the industry’s production constraints and foster the success of cell and gene therapies” said Hugues Bultot, CEO of Univercells and Exothera.

Following initial activities in established facilities in Gosselies and Nivelles in Belgium, Exothera’s capabilities will be housed at Univercells’ recently bought 15,000 m2 site in Jumet, also in Belgium.

The Jumet site will be revamped to house labs, cleanrooms and GMP manufacturing areas for clinical and commercial production.

The flexible GMP areas at Jumet will contain Exothera’s CDMO activities and ongoing Univercells vaccine development and manufacturing initiatives, with capacity for rapid response programs.

Exothera is currently pursuing support opportunities for COVID-19 vaccine innovators.